[{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"ACh receptor||ACh release","graph1":"Urology","graph2":"Phase II","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UroGen Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"UroGen Pharma \/ Undisclosed"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"UGN-301","moa":"Cytotoxic T-lymphocyte protein 4","graph1":"Oncology","graph2":"Phase I","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"UroGen Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"UroGen Pharma \/ Undisclosed"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Imiquimod","moa":"||Cytotoxic T-lymphocyte protein 4","graph1":"Oncology","graph2":"IND Enabling","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"UroGen Pharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"UroGen Pharma \/ Undisclosed"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Collaboration","leadProduct":"Imiquimod","moa":"||Cytotoxic T-lymphocyte protein 4","graph1":"Oncology","graph2":"IND Enabling","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"UroGen Pharma \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"5","companyTruncated":"UroGen Pharma \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Zalifrelimab","moa":"Cytotoxic T-lymphocyte protein 4","graph1":"Oncology","graph2":"IND Enabling","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UroGen Pharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"UroGen Pharma \/ Undisclosed"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Hydrogel","sponsorNew":"UroGen Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UroGen Pharma \/ Undisclosed"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Hydrogel","sponsorNew":"UroGen Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UroGen Pharma \/ Undisclosed"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Hydrogel","sponsorNew":"UroGen Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UroGen Pharma \/ Undisclosed"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"medac","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibiotic","year":"2024","type":"Licensing Agreement","leadProduct":"Mitomycin","moa":"DNA","graph1":"Oncology","graph2":"Preclinical","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"UroGen Pharma \/ UroGen Pharma","highestDevelopmentStatusID":"4","companyTruncated":"UroGen Pharma \/ UroGen Pharma"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"UroGen Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UroGen Pharma \/ Undisclosed"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"UroGen Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UroGen Pharma \/ Undisclosed"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"UroGen Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UroGen Pharma \/ Undisclosed"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"UroGen Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UroGen Pharma \/ Undisclosed"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"UroGen Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UroGen Pharma \/ Undisclosed"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"UroGen Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UroGen Pharma \/ Undisclosed"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"UroGen Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UroGen Pharma \/ Undisclosed"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"UroGen Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UroGen Pharma \/ Undisclosed"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"UroGen Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UroGen Pharma \/ Undisclosed"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"UroGen Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UroGen Pharma \/ Undisclosed"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"UroGen Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UroGen Pharma \/ Undisclosed"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"UroGen Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UroGen Pharma \/ Undisclosed"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"UroGen Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UroGen Pharma \/ Undisclosed"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"UroGen Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UroGen Pharma \/ Undisclosed"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Tanner Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"UroGen Pharma \/ Tanner Pharma","highestDevelopmentStatusID":"15","companyTruncated":"UroGen Pharma \/ Tanner Pharma"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"UroGen Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UroGen Pharma \/ Undisclosed"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"UroGen Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UroGen Pharma \/ Undisclosed"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"UroGen Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UroGen Pharma \/ Undisclosed"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"UroGen Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UroGen Pharma \/ Undisclosed"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Private Placement","leadProduct":"Mitomycin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"UroGen Pharma","amount2":0.12,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.12,"dosageForm":"Solution","sponsorNew":"UroGen Pharma \/ BofA Securities","highestDevelopmentStatusID":"15","companyTruncated":"UroGen Pharma \/ BofA Securities"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"UroGen Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UroGen Pharma \/ Undisclosed"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"UroGen Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UroGen Pharma \/ Undisclosed"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"UroGen Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UroGen Pharma \/ Undisclosed"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"UroGen Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UroGen Pharma \/ Undisclosed"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"UroGen Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UroGen Pharma \/ Undisclosed"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"UroGen Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UroGen Pharma \/ Undisclosed"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"UroGen Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UroGen Pharma \/ Undisclosed"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"UroGen Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UroGen Pharma \/ Undisclosed"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"UroGen Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UroGen Pharma \/ Undisclosed"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"UroGen Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UroGen Pharma \/ Undisclosed"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Neopharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Licensing Agreement","leadProduct":"Mitomycin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"UroGen Pharma \/ Neopharm","highestDevelopmentStatusID":"15","companyTruncated":"UroGen Pharma \/ Neopharm"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"RTW Investments","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Funding","leadProduct":"Mitomycin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"UroGen Pharma","amount2":0.080000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Solution","sponsorNew":"UroGen Pharma \/ RTW Investments","highestDevelopmentStatusID":"15","companyTruncated":"UroGen Pharma \/ RTW Investments"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"TD Cowen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Public Offering","leadProduct":"Mitomycin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"UroGen Pharma","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.11,"dosageForm":"Solution","sponsorNew":"UroGen Pharma \/ TD Cowen","highestDevelopmentStatusID":"15","companyTruncated":"UroGen Pharma \/ TD Cowen"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"TD Cowen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Public Offering","leadProduct":"Mitomycin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"UroGen Pharma","amount2":0.11,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.11,"dosageForm":"Solution","sponsorNew":"UroGen Pharma \/ TD Cowen","highestDevelopmentStatusID":"15","companyTruncated":"UroGen Pharma \/ TD Cowen"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA","graph1":"Oncology","graph2":"Phase IV","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"UroGen Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"UroGen Pharma \/ Undisclosed"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"UroGen Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UroGen Pharma \/ Undisclosed"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"UGN-103","moa":"DNA alkylation","graph1":"Oncology","graph2":"Phase III","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Hydrogel","sponsorNew":"UroGen Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UroGen Pharma \/ Undisclosed"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"IconOVir Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2025","type":"Acquisition","leadProduct":"ICVB-1042","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UroGen Pharma \/ UroGen Pharma","highestDevelopmentStatusID":"6","companyTruncated":"UroGen Pharma \/ UroGen Pharma"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"UGN-104","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Hydrogel","sponsorNew":"UroGen Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UroGen Pharma \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by UroGen Pharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Formnext Forum
                          Not Confirmed
                          Formnext Forum
                          Not Confirmed

                          Details : Zusduri (mitomycin) is a DNA synthesis inhibitor which is currently being evaluated in phase 3 clinical trials for the treatment of low-grade, intermediate-risk non-muscle invasive bladder cancer.

                          Product Name : Zusduri

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          June 12, 2025

                          Lead Product(s) : Mitomycin

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Formnext Forum
                          Not Confirmed
                          Formnext Forum
                          Not Confirmed

                          Details : UroGen expand its oncology pipeline portfolio through the acquisition of assets relating to a next-gen oncolytic virus ICVB-1042 from IconOVir Bio.

                          Product Name : Undisclosed

                          Product Type : Microorganism

                          Upfront Cash : Undisclosed

                          February 20, 2025

                          Lead Product(s) : ICVB-1042

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Recipient : IconOVir Bio

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          03

                          Formnext Forum
                          Not Confirmed
                          Formnext Forum
                          Not Confirmed

                          Details : UGN-102 (mitomycin) is a DNA synthesis inhibitor which is currently being evaluated in phase 3 clinical trials for the treatment of low-grade, intermediate-risk non-muscle invasive bladder cancer.

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          February 14, 2025

                          Lead Product(s) : Mitomycin

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Formnext Forum
                          Not Confirmed
                          Formnext Forum
                          Not Confirmed

                          Details : Jelmyto® (mitomycin) is a FDA approved pyelocalyceal solution is a mitomycin-containing 4 mg mitomycin per mL gel indicated for primary chemoablative treatment of LG-UTUC in adults.

                          Product Name : Jelmyto

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          January 22, 2025

                          Lead Product(s) : Mitomycin

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Formnext Forum
                          Not Confirmed
                          Formnext Forum
                          Not Confirmed

                          Details : UGN-104 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Carcinoma, Transitional Cell.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          January 14, 2025

                          Lead Product(s) : UGN-104

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Formnext Forum
                          Not Confirmed
                          Formnext Forum
                          Not Confirmed

                          Details : UGN-102 (mitomycin) is a DNA synthesis inhibitor which is currently being evaluated in phase 3 clinical trials for the treatment of low-grade, intermediate-risk non-muscle invasive bladder cancer.

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          December 05, 2024

                          Lead Product(s) : Mitomycin

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Formnext Forum
                          Not Confirmed
                          Formnext Forum
                          Not Confirmed

                          Details : Jelmyto® (mitomycin) is a FDA approved pyelocalyceal solution is a mitomycin-containing reverse thermal gel, indicated for primary chemoablative treatment of LG-UTUC in adults.

                          Product Name : Jelmyto

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          November 26, 2024

                          Lead Product(s) : Mitomycin

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Formnext Forum
                          Not Confirmed
                          Formnext Forum
                          Not Confirmed

                          Details : UGN-102 (mitomycin) is a DNA synthesis inhibitor which is currently being evaluated in phase 3 clinical trials for the treatment of low-grade, intermediate-risk non-muscle invasive bladder cancer.

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          October 15, 2024

                          Lead Product(s) : Mitomycin

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Formnext Forum
                          Not Confirmed
                          Formnext Forum
                          Not Confirmed

                          Details : UGN-103 is a next-generation novel mitomycin-based formulation, in development for the treatment of low-grade intermediate-risk non-muscle invasive bladder cancer

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          October 02, 2024

                          Lead Product(s) : Mitomycin

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Formnext Forum
                          Not Confirmed
                          Formnext Forum
                          Not Confirmed

                          Details : UGN-102 (mitomycin) is a DNA synthesis inhibitor which is currently being evaluated in phase 3 clinical trials for the treatment of low-grade, intermediate-risk non-muscle invasive bladder cancer.

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          August 14, 2024

                          Lead Product(s) : Mitomycin

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank